# US 2026/0098071 A1 · GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0098071 A1 - Document ID: US20260098071A1 - Status: Published application - Kind: A1 - Application number: 18/968,327 - Filed: 2024-12-04 - Published: 2026-04-09 - Earliest claimed: 2024-10-09 - Inventors: Tao Sun - Web page: https://patentgrep.com/patent/US20260098071A1 ## CPC - C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) - A61P 3/04: Anorexiants; Antiobesity agents - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 25/22: Anxiolytics - A61P 25/24: Antidepressants - C07K 14/605: Glucagons - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present disclosure relates to a novel human glucagon-like peptide-1 (GLP-1) analog. Compared with the natural sequence of GLP-1, the GLP-1 analog has a remarkable effect in improving GLP-1-related diseases such as obesity, type 2 diabetes mellitus (T2DM), and fatty liver (FL), as well as mood disorders such as anxiety and depression. ## Claims ### Claim 1 A glucagon-like peptide-1 (GLP-1) analog, comprising amino acid sequences of Formula I: Formula I (SEQ ID NO: 2) HX2X3 GTF TSD VSS YLE GQA AKX21 FIA WLX27 KX29RX31 wherein, X2 is selected from the group consisting of valine, isoleucine, glycine, threonine, leucine and serine; X3 is selected from the group consisting of serine and alanine; X21 is selected from the group consisting of arginine and lysine; X27 is selected from the group consisting of serine and alanine; X29 is selected from the group consisting of alanine, serine, threonine and methionine; and X31 is selected from the group consisting of alanine, serine, threonine and methionine. ### Claim 2 (depends on 1) A method of treating GLP-1 related diseases, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 1 to a subject in need thereof. ### Claim 3 (depends on 2) The method according to claim 2, the GLP-1 related diseases comprise at least one of obesity and related complications, diabetes mellitus and related complications, glucose intolerance and related diseases caused therefrom, hyperglycemia, hyperinsulinemia, hypertension, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, cardiovascular disease, stroke, related diseases caused by intestinal permeability disorders such as inflammatory bowel syndrome and/or dyspepsia and/or ulcerative colitis and/or Crohn's disease, apoplexy and/or hemorrhagic apoplexy, neuroinflammation, rheumatic or rheumatoid arthritis, kidney disease, asthma, chronic obstructive pulmonary disease, dysmetabolic syndrome, anxiety, depression, mood disorders and neurodegenerative diseases of Alzheimer's disease, and systemic lupus erythematosus. ### Claim 4 (depends on 1) A method of reducing food intake, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 1 to a subject in need thereof. ### Claim 5 (depends on 1) A method of increasing insulin sensitivity, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 1 to a subject in need thereof. ### Claim 6 (depends on 1) A method of inhibiting fat accumulation, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 1 to a subject in need thereof. ### Claim 7 (depends on 6) The method according to claim 6, wherein the fat accumulation comprises subcutaneous fat accumulation, inter-organ fat accumulation, and hepatic fat accumulation. ### Claim 8 (depends on 1) A composition, comprising the GLP-1 analog according to claim 1 and a pharmaceutically acceptable excipient. ### Claim 9 (depends on 8) A food additive, comprising the composition according to claim 8. ### Claim 10 (depends on 1) A food additive, comprising the GLP-1 analog according to claim 1. ### Claim 11 A GLP-1 analog, comprising a polypeptide sequence of Formula II: Formula II (SEQ ID NO: 1) HGE GTF TSD VSS YLE GQA AKE FIA WLV KSRA ### Claim 12 (depends on 11) A method of treating GLP-1 related diseases, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 11 to a subject in need thereof. ### Claim 13 (depends on 12) The method according to claim 12, the GLP-1 related diseases comprise at least one of obesity and related complications, diabetes mellitus and related complications, glucose intolerance and related diseases caused therefrom, hyperglycemia, hyperinsulinemia, hypertension, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, cardiovascular disease, stroke, related diseases caused by intestinal permeability disorders such as inflammatory bowel syndrome and/or dyspepsia and/or ulcerative colitis and/or Crohn's disease, apoplexy and/or hemorrhagic apoplexy, neuroinflammation, rheumatic or rheumatoid arthritis, kidney disease, asthma, chronic obstructive pulmonary disease, dysmetabolic syndrome, anxiety, depression, mood disorders and neurodegenerative diseases of Alzheimer's disease, and systemic lupus erythematosus. ### Claim 14 (depends on 11) A method of reducing food intake, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 11 to a subject in need thereof. ### Claim 15 (depends on 11) A method of increasing insulin sensitivity, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 11 to a subject in need thereof. ### Claim 16 (depends on 11) A method of inhibiting fat accumulation, comprising administering a therapeutically effective amount of the GLP-1 analog according to claim 11 to a subject in need thereof. ### Claim 17 (depends on 16) The method according to claim 16, wherein the fat accumulation comprises subcutaneous fat accumulation, inter-organ fat accumulation, and hepatic fat accumulation. ### Claim 18 (depends on 11) A composition, comprising the GLP-1 analog according to claim 11 and a pharmaceutically acceptable excipient. ### Claim 19 (depends on 18) A food additive, comprising the composition according to claim 18. ### Claim 20 (depends on 11) A food additive, comprising the GLP-1 analog according to claim 11.